Anticoagulation therapy CSVT Cerebral sinovenous thrombosis ICH Intracerebral haemorrhage AIM To determine whether anticoagulation therapy (ACT) in the treatment of neonatal cerebral sinovenous thrombosis (CSVT) improves outcomes, in the presence or absence of pre-existing intracerebral haemorrhage (ICH).
sensorimotor impairments, 3 and mortality. 2 The clinical presentations of neonatal CSVT are varied. Although seizures are the most frequently reported presenting feature, lethargy or reduced consciousness, apnoea, hypertonia or hypotonia, focal motor deficits, and respiratory distress have all been reported. [2] [3] [4] [5] CSVT may also be detected in asymptomatic infants imaged for unrelated reasons. 2, 4 Pathogenesis is multifactorial and includes various maternal and neonatal factors, as well as prothrombotic coagulant factors.
Cerebral sinovenous thrombosis also occurs in adults and children, where the mainstay of treatment is anticoagulation with unfractionated or low-molecular-weight heparin to increase the rate of resolution, and prevent the propagation of thrombus. This may reduce the extent of thrombus-related venous infarct, and haemorrhagic transformation. This treatment is supported by a reasonable evidence base in the adult population 6 and there is some evidence for its use in the paediatric population. 7 Nonetheless, there remains extensive variation in practice in both populations. 8, 9 There is continuing uncertainty over the use of anticoagulation in neonatal CSVT. It may be considered an entity discrete from paediatric and adult CSVT owing to both the unique but transient risk factors present in the neonatal period and the particular fragility of the neonatal brain. 10 Furthermore, this population has a high incidence of pre-existing intracerebral haemorrhage (ICH) at the time of diagnosis. Treatment with anticoagulation therapy (ACT) could then carry a potential risk of extending existing haemorrhage, resulting in poorer outcomes.
The use of ACT in the management of neonatal CSVT has been included in several guidelines 7, 11 yet its use in infants with pre-existing ICH remains contentious. Few studies have attempted to assess the safety and efficacy of ACT in neonatal CSVT, and, crucially, the evidence for ACT has not been considered in infants with pre-existing ICH where treatment decisions may be the most challenging.
In this systematic review we assess the evidence for ACT in the treatment of neonatal CSVT both in the presence and absence of pre-existing ICH. Our objective was to test the hypothesis that ACT in the treatment of CSVT in neonatal infants (<28d of age or <44wks postmenstrual age at presentation and with or without pre-existing ICH) is associated with lower mortality before discharge, reduced risk of extension of pre-existing haemorrhage, reduced rates of thrombus propagation, and improved neurodevelopmental outcomes at 2 years of age.
METHOD
No protocol was published in advance of this systematic review and meta-analysis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library); MEDLINE via Ovid SP (January 1966-October 1st, 2017); Embase via Ovid SP (January 1980-October 1st, 2017); CINAHL via EBSCO Host (1982-October 1st, 2017) and Web of Science (1985-October 1st, 2017). We used the Cochrane highly sensitive search strategy for identifying randomized controlled trials as suggested in the Cochrane Handbook for Systematic Reviews of Interventions. 12 Medical Subject Headings (MeSH) were used when available as shown in Table I . An additional free-text search was conducted for each search engine using 'Newborn' AND ('cerebral venous' OR 'cerebral sinovenous') AND ('thrombus' OR 'thrombosis'). In addition, we searched the following registries: http://www.controlled-trials.com; http://clinicaltria ls.gov; http://www.anzctr.org.au. We also checked the reference lists of all identified studies for further relevant ones. Conference abstracts were not included in the systematic review, but were used to identify published papers.
Data collection and analysis
After identifying studies using the electronic databases, the bibliographies were reviewed to identify additional relevant studies, and a full-text second-stage screening was performed by two reviewers (TR, RS). Initial records were screened for relevance, and the abstracts of those records of potential relevance were reviewed.
Studies that potentially fulfilled inclusion criteria based on the abstract were reviewed as full text. A decision was made about eligibility for inclusion, and any disagreement between reviewers was resolved by discussion. A standardized data extraction form was used by both reviewers. 13 Another reviewer (TA) assessed the quality of studies independently and any differences were reconciled by mutual agreement. The details of all excluded studies are listed with reason for exclusion in Table II .
Inclusion criteria
We considered data from retrospective and prospective cohort studies, case series, and randomized controlled studies evaluating outcomes of CSVT treated with anticoagulation or no anticoagulation. Studies were included if they involved infants either younger than 28 days of age or younger than 44 weeks postmenstrual age at time of diagnosis of CSVT in which anticoagulation was considered in the presence or absence of intracranial haemorrhage. Primary outcomes considered were death or neurological sequelae at 2 years' follow-up and death before discharge from hospital. Secondary outcomes considered were extension of thrombus and extension of intracranial haemorrhage. Characteristics of included studies are summarized in Table III .
Assessment of risk of bias in included studies
Risk of bias was independently assessed by two reviewers (TR, RS) using the Cochrane Collaboration's domainbased tool for assessing risk of bias. Selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias were scored. An overall risk of bias for each • ACT may reduce thrombus propagation.
• No evidence of increased morbidity or mortality with ACT was demonstrated.
• A position of equipoise is justified, supporting the need for placebo-controlled randomized trials.
Reviewstudy was 'high risk of bias', 'low risk of bias', or 'unclear risk of bias'. This was done according to guidance in the Cochrane Handbook for Systematic Reviews of Interventions. 12 Any disagreements were resolved by consensus, or, where necessary, by discussion with third reviewer (TA).
Measures of treatment effect
Categorical data were extracted for each intervention group, and the risk ratio and risk difference calculated. If the risk difference was statistically significant, the number needed to treat or harm was calculated. Study included 52 neonatal infants, 43 with pre-existing ICH. Now outcomes were presented with sufficient detail for meta-analysis deVeber et al. 27 Study included eight neonatal infants; however, no outcome data could be extracted as presented as part of a larger paediatric study deVeber et al. 1 Study included 69 neonatal infants with CSVT; however, no outcome data could be extracted for relevant groups (neonatal infants receiving or not receiving ACT) Grunt et al. 28 Twenty-one neonatal infants with CSVT. Insufficient data presented to include in meta-analysis Jordan et al. 5 Eighty-four neonatal infants with CSVT, 43 of whom received antithrombotic medication. No data for specified outcome measures could be extracted Kenet et al. 19 Seventy-five neonatal infants with CSVT. Unable to extract data for specified outcome measures depending on administration of ACT Steinlin et al. 29 Seventeen CSVT in paediatric population. Unable to extract neonatal data for specified outcome measures Tuckuviene et al. 23 Seven neonatal infants included. Unable to extract data for specified outcome measures Vieira et al. 24 Possibly six neonatal infants included, although varying use of terminology. Not possible to extract data for specified outcome measures Wasay et al. 30 Twenty-five neonatal infants included. Not possible to extract data for specified outcome measures ICH, intracerebral haemorrhage; CSVT, cerebral sinovenous thrombosis; ACT, anticoagulation therapy.
Assessment of heterogeneity
Heterogeneity was quantified with the I 2 statistic calculated as described in the Cochrane Handbook for Systematic Reviews of Interventions. 12 The thresholds for interpreting I 2 are as follows: 0% to 40%, may represent insignificant heterogeneity; 30% to 60%, may represent moderate heterogeneity; 50% to 90%, may represent substantial heterogeneity; greater than 75%, may represent considerable heterogeneity. Were I 2 to exceed 75%, we would have conducted a sensitivity analysis to explain the source of heterogeneity.
Assessment of reporting biases
Where meta-analysis was undertaken, a funnel plot was used to assess publication bias.
Data synthesis
Meta-analysis was performed using RevMan (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) with a fixed-effect model where there were two or more studies with comparable populations and treatment interventions. We present our results with 95% confidence intervals (CIs). We assessed risk ratios and risk differences. The outcomes of comparable trials were analysed with 95% CIs to estimate treatment effect. If appropriate, we compared results using forest plots with the risk ratio as the point estimate for dichotomous outcomes.
RESULTS
Seven studies presented outcomes from neonatal CSVT with sufficient detail to be included in meta-analysis ( Fig. 1 and Table III ). Our assessment of bias is presented in Figure 2 . Fitzgerald et al. 4 performed a single-centre retrospective review of 42 patients with neonatal CSVT, of whom 25 had pre-existing ICH; three without ICH received ACT. Gentilomo et al.
14 conducted a single-centre retrospective review identifying five neonatal infants with CSVT of whom two received ACT. Kenet et al. 15 identified eight individuals with neonatal CSVT in a multicentre case-control study, four of whom received ACT. Kersbergen et al. 16 identified 10 individuals with neonatal CSVT in a single centre of whom seven received ACT. Moharir et al. 17 published two retrospective analyses of cases of neonatal CSVT that were prospectively enrolled into a study. In the first study containing 83 cases of neonatal CSVT, 59 neonatal infants had ICH at presentation of whom 21 received ACT. Of the remaining 24 without ICH at presentation, 17 received ACT. 17 In the latter study, 71 of 104 neonatal infants had ICH at presentation, of whom 29 received ACT. Of the remaining 33 without ICH at presentation, 24 received ACT. 3 The data from patients in the earlier study were included in the later study. Incomplete reporting of outcome variables required inclusion of the earlier study where data were not presented in the larger study. 3 Pergami and Abraham 18 conducted a retrospective review of neonatal CSVT, identifying 22 patients of whom five received ACT without complication.
In none of the studies was treatment allocated by randomization. Decision to treat was based in all cases on local protocols, and clinicians' assessments of the likelihood of benefit. This would be a significant source of bias in the results of all the included studies. Sufficient data were reported to meta-analyse the effect of ACT on mortality before discharge in neonatal infants with pre-existing ICH and without (Figs 3-6) . In neonatal infants without pre-existing ICH there was no effect of anticoagulant therapy on mortality before hospital discharge (risk ratio 0.91; 95% CI 0.23-3.57). There was a non-significant trend towards lower mortality before hospital discharge in neonatal infants with pre-existing ICH who received ACT compared with those who did not (risk ratio 0.14; 95% CI 0.02-1.21).
Two studies presented sufficient data to meta-analyse the effect of ACT on the incidence of extension of ICH in neonatal infants with pre-existing ICH. 16, 18 This showed a non-significant trend towards lower rates of extension of Although several studies reported neurodevelopmental outcomes, [2] [3] [4] 14, 16, 17, 19 in all cases the time point and variable tools for assessment precluded comparison. In one study, predictors of poor neurological outcome at last follow-up were examined. Not receiving ACT was a predictor of poorer neurodevelopmental outcome on univariate but not multivariate analysis. 17 No meta-analysis of outcome data was possible.
DISCUSSION
In this meta-analysis, in-hospital mortality did not differ significantly between those who received ACT and those who did not. However, there was a trend towards lower mortality in those infants with pre-existing ICH receiving ACT.
Our meta-analysis suggests a significantly reduced risk of thrombus propagation in neonatal infants with CSVT who received ACT. There was no greater risk of new or extension of haemorrhage in those infants with pre-existing ICH who received ACT compared with those who did not. Although there is reasonable evidence for the use of anticoagulation in CSVT in adults 20 and some evidence for safety and efficacy in children, 7 there are limited data to guide usage of ACT in neonatal infants with CSVT. Nonetheless there are expert consensus guidelines which provide varying degrees of support for using anticoagulation in neonatal infants. 11, 21, 22 Although we identified several studies that reported the use of ACT for CSVT in the neonatal population, they were limited to retrospective reviews of cases. 2, 4, 5, [14] [15] [16] 23, 24 Of interest, none of these studies reported a significantly higher rate of intracranial haemorrhage in neonatal infants who received ACT. In contrast, in the largest prospective study identified, Moharir et al. 17 reported a slightly higher but non-significant rate of major ICH in 6% of anticoagulated neonatal infants compared with 3% of those untreated (p=0.536). Our meta-analysis of the few studies that reported outcomes according to both the presence of pre-existing ICH and ACT suggested that the risk of extension in infants with pre-existing ICH is not increased by ACT.
In this meta-analysis the risk of death before discharge was not higher in infants who received ACT than in comparison groups, either in the presence or absence of preexisting ICH. In the presence of ICH there was a trend towards lower mortality in those who received ACT. However, as the use of anticoagulation would have been based on clinician assessment (and perceived stability) of individual infants, there is a high risk of selection bias and these results must be interpreted with caution.
This meta-analysis demonstrated a significant benefit of ACT in reducing the risk of thrombus propagation. 
Review
Propagation of thrombus has been associated with an increased rate of subsequent venous infarction. 3 Of note, many of the included neonatal infants were initiated on ACT only after demonstrated propagation of thrombus after diagnosis and an initial clinical decision not to treat, with associated close monitoring with imaging. Those who were not started on ACT were monitored for propagation with magnetic resonance venography, whereas those treated were more likely to be imaged using computed tomography to assess for ACT-related haemorrhage. 3 The reduced sensitivity of computed tomography in detecting thrombus would make a degree of detection bias highly likely, with those reimaged with magnetic resonance venography more likely to have extension detected.
There is a reasonable explanation for the benefit of anticoagulation, as haemorrhage in the context of neonatal CSVT is most likely to arise from venous infarction due to raised venous pressure. While the risk of bias is high in these studies, there seems to be some support for a benefit of ACT in reducing thrombus propagation. This may plausibly decrease venous pressures and therefore reduce both further parenchymal damage through venous infarction and the risk of haemorrhagic transformation.
The studies included in this review comprised a heterogeneous population. Numerous risk factors for CSVT and ICH vary between the term and preterm population. The studies included in this systematic review included both infants born at term and preterm; however, none of the studies presented data in such a way that these two groups could be analysed separately. This is an important consideration for future studies, as the risks and benefits of ACT may differ between these two populations. Furthermore, studies addressed the varying underlying causes of CSVT differently. Pergami and Abraham 18 excluded infants with CSVT secondary to CNS infection who were included in other studies. Short-and long-term outcomes may be heavily influenced by the precipitating condition, yet it was not possible to explore this with the studies available.
Across the studies there was variation in the ACT used, in the timing of ACT (which in some cases was delayed until thrombus propagation was demonstrated), in the agents used, and in the dosing regime and duration of treatment. Although treatment regimes have been proposed, 7 these are based on expert opinion. As most of the published studies in the treatment of neonatal CSVT are retrospective, this has not been formally evaluated.
The meta-analysis reviewed a few, small, non-randomized studies and therefore caution must be exercised in interpreting the results. 25 Nonetheless, it has allowed a comparison of studies to be undertaken and demonstrated some consistency in findings, which may inform future research design. 26 
CONCLUSION
Treatment with ACT is variably used in the management of neonatal CSVT, but there remain insufficient data to assess its safety and efficacy. Although the results of this meta-analysis provide some support for the use of ACT in this population, the studies included are at a high risk of bias, and caution must be exercised in their interpretation. However, the results justify a position of equipoise and support the need for well-designed randomized controlled trials of ACT in this population.
